Evidence map›Paper›PMID 37702881›Full record

ArticleMolecular biotechnology2025

Effects of Zofenopril on Arterial Stiffness in Hypertension Patients.

Benjamin Palić, Ivica Brizić, Emina Karahmet Sher, Ivona Cvetković, Amina Džidić-Krivić, Heba Taha Mohmmed Abdelghani, Farooq Sher

Open access · hybridAbstract read
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Benjamin PalićDepartment of Internal Medicine, University Clinical Hospital Mostar, 88000, Mostar, Bosnia and Herzegovina.
Ivica BrizićDepartment of Internal Medicine, University Clinical Hospital Mostar, 88000, Mostar, Bosnia and Herzegovina.
Emina Karahmet SherDepartment of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK. Emina.Sher@isest.org.
Ivona CvetkovićDepartment of Laboratory Diagnostics, University Clinical Hospital Mostar, 88000, Mostar, Bosnia and Herzegovina.
Amina Džidić-KrivićDepartment of Neurology, Cantonal Hospital Zenica, 72000, Zenica, Bosnia and Herzegovina.
Heba Taha Mohmmed AbdelghaniDepartment of Physiology of Physical Activity, College of Sport Sciences and Physical Activity, King Saud University, 11451, Riyadh, Saudi Arabia.
Farooq SherDepartment of Engineering, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK. Farooq.Sher@ntu.ac.uk.ORCID http://orcid.org/0000-0003-2890-5912
University Clinical Hospital Mostar · BANottingham Trent University · GBKing Saud University · SAUniversity of Zenica · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) reduce arterial stiffness beyond their antihypertensive effect. Studies showed that sulfhydryl ACEIs have the antioxidative potential to improve endothelial function, which might have a clinical effect on arterial distensibility. However, there are no studies that directly compare the effects of sulfhydryl (zofenopril) and non-sulfhydryl ACEIs (enalapril) on arterial stiffness. Therefore, this prospective study aims to compare the effects of enalapril and zofenopril on arterial stiffness and oxidative stress in both short- and long-term treatment of arterial hypertension (AH). Baseline and post-treatment peripheral and central arterial pressure indices, augmentation index (Aix), aortic pulse wave velocity (ao-PWV), serum levels of oxidized low-density cholesterol lipoprotein, LDL and uric acid (UA) were measured. The results showed that acute treatment with zofenopril, in contrast to enalapril, significantly decreased peripheral and central Aix (p < 0.001). Chronic treatment with zofenopril showed a superior effect over enalapril on the reduction of the peripheral systolic arterial pressure with reduction of ao-PWV (p = 0.004), as well as a reduction in peripheral Aix (p = 0.021) and central Aix (p = 0.021). Therefore, this study indicates that zofenopril has beneficial effects on the reduction of arterial stiffness compared to enalapril. It has potent clinical efficacy in AH treatment and further studies should compare its safety and long-term efficacy to other AH drugs that would aid clinicians in treating AH and other various cardiovascular diseases that have arterial stiffness as a common denominator.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilHypertensionVascular StiffnessAgedBlood PressureEnalaprilFemaleHumansMaleMiddle AgedOxidative StressProspective StudiesPulse Wave AnalysisUric AcidAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilEnalaprilUric AcidzofenoprilACE inhibitorsHypertensionLipoproteinsSulfhydryl groupVascular StiffnessZofenopril

Identifiers

PMID37702881
PMCPMC12413429
OpenAlexW4386704637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.